Athira Pharma to Participate in Upcoming June Conferences

Athira Pharma to Participate in Upcoming June Conferences

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the following upcoming investor conferences in June.

Jefferies Healthcare Conference
Format: Fireside Chat
Date and Time: Wednesday, June 5, 2024, from 4:30 p.m. ET- 4:55 p.m. ET
Location: Marriott Marquis, New York City

Goldman Sachs 45 th Annual Healthcare Conference
Format: Fireside Chat
Date and Time: Wednesday, June 12, 2024, from 2:00 p.m. ET- 2:35 p.m. ET
Location: Loews Miami Beach Hotel, Miami

Live webcasts of the fireside chats can be accessed from the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations-investor . An archived replay of the webcasts will be available for at least 30 days following the event.

About Athira Pharma, Inc.
Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to alter the course of neurological diseases by advancing its pipeline of therapeutic candidates that modulate the neurotrophic HGF system, including fosgonimeton, which is being evaluated for the potential treatment of mild-to-moderate Alzheimer's disease in the Phase 2/3 LIFT-AD trial that is expected to report topline data in the second half of 2024. For more information, visit www.athira.com . You can also follow Athira on Facebook , LinkedIn and @athirapharma on X , formerly known as Twitter   , and Instagram .

Forward-Looking Statements
This communication contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding: product candidates as a potential treatment for Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, and other neurodegenerative diseases; future development plans; the anticipated reporting of data; expectations regarding the potential efficacy and commercial potential of Athira's product candidates; and Athira's ability to advance its product candidates into later stages of development. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "on track," "would," "expect," "plan," "believe," "intend," "pursue," "continue," "suggest," "potential," and similar expressions. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the data from preclinical and clinical trials may not support the safety, efficacy and tolerability of Athira's product candidates; development of product candidates may cease or be delayed; regulatory authorities could object to protocols, amendments and other submissions; future potential regulatory milestones for product candidates, including those related to current and planned clinical studies, may be insufficient to support regulatory submissions or approval; Athira may not be able to recruit sufficient patients for its clinical trials; the outcome of legal proceedings that have been or may in the future be instituted against Athira, its directors and officers; possible negative interactions of Athira's product candidates with other treatments; Athira's assumptions regarding its financial condition and the sufficiency of its cash, cash equivalents and investments to fund its planned operations may be incorrect; adverse conditions in the general domestic and global economic markets; the impact of competition; regulatory agencies may be delayed in reviewing, commenting on or approving any of Athira's clinical development plans as a result of pandemics or health epidemics, which could further delay development timelines; the impact of expanded product development and clinical activities on operating expenses; the impact of new or changing laws and regulations; as well as the other risks detailed in Athira's filings with the Securities and Exchange Commission from time to time. These forward-looking statements speak only as of the date hereof and Athira undertakes no obligation to update forward-looking statements. Athira may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the forward-looking statements.

Investor Contacts:
Julie Rathbun
Athira Pharma
Julie.rathbun@athira.com
206-769-9219


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

ATHA
The Conversation (0)
SAGA Metals Reports Assay Results and Plans Drill Program at Double Mer Uranium Project

SAGA Metals Reports Assay Results and Plans Drill Program at Double Mer Uranium Project

Saga Metals Corp. ("SAGA" or the "Company"), a North American exploration company focused on critical mineral discovery in Canada, is pleased to share assay results from its inaugural field program at the Double Mer Uranium Project, located in eastern Labrador, Canada.

Key Updates from the Double Mer Uranium Project

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Canadian Securities Exchange Reports October 2024 Performance Figures

Canadian Securities Exchange Reports October 2024 Performance Figures

The Canadian Securities Exchange ("CSE" or "the Exchange") today announced market statistics for October 2024.

October 2024 Operating Statistics

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
SAGA Metals Prepares Maiden Drill Program at Double Mer Uranium Project

SAGA Metals Prepares Maiden Drill Program at Double Mer Uranium Project

Saga Metals Corp. (" TSXV: SAGA ") (" FSE: 20H" ) (" SAGA " or the " Company "), a North American exploration company focused on discovering critical minerals, is pleased to announce its plans for a maiden drill program at the Double Mer Uranium project.

Key Highlights for the maiden drill program at the Double Mer Uranium Project:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Greenridge Exploration Enters into Binding Arrangement Agreement to Acquire ALX Resources Corp.

Greenridge Exploration Enters into Binding Arrangement Agreement to Acquire ALX Resources Corp.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Greenridge Exploration Inc. (CSE: GXP) (FSE: HW3)  ("Greenridge" or the "Company") and alx resources corp. ("ALX" and collectively with Greenridge, the "Parties") (TSXV: AL) (FSE: 6LLN) (OTC: ALXEF) are pleased to announce the signing of a binding arrangement agreement (the "Arrangement Agreement") dated October 11, 2024 pursuant to which Greenridge will acquire all of the outstanding and issued common shares of ALX (the "Transaction"). The Transaction is an arm's length transaction that will create a leading Canadian uranium exploration company with interests in sixteen (16) uranium exploration projects that total approximately 220,000 hectares across renowned Canadian uranium districts including the Athabasca Basin, Thelon Basin and Elliot Lake. The combined entity will have interests in an additional thirteen (13) lithium, nickel, gold and copper properties across Canada. The Arrangement Agreement follows the non-binding letter of intent announced by the Company on September 5, 2024.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
SAGA Metals Completes IPO with Focus on Uranium Exploration and Rio Tinto Partnership

SAGA Metals Completes IPO with Focus on Uranium Exploration and Rio Tinto Partnership

Saga Metals Corp. (" TSXV: SAGA ") (" SAGA " or the " Company "), a North American exploration company focused on critical mineral discovery in Canada, is pleased to announce the successful closing of its initial public offering (IPO) and provide updates on its major projects. SAGA shares began trading on the TSX Venture Exchange (TSXV) under the symbol "SAGA" on September 24, 2024.

A Strategic Focus on Critical Minerals in North America

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Invion Limited

Invion Doses First Patient in Phase I/II Non-Melanoma Skin Cancer Trial

Invion Limited (ASX: IVX) (“Invion” or the “Company”) is pleased to announce the dosing of the first patient in its Phase I/II non- melanoma skin cancer (NMSC) trial conducted at Veracity Clinical Research (Veracity) in Brisbane.

Keep reading...Show less
BPH Global

Seaweed Extraction of Critical Minerals R&D

BPH Global (BP8:AU) has announced Seaweed Extraction of Critical Minerals R&D

Download the PDF here.

Resonance Health Ltd

Resonance Contracted by Major Global Pharma Company for Clinical Drug Trial Worth $13.775 Million over 24 Months

Resonance Health Ltd (ASX: RHT) (Resonance or the Company) advises that it has been contracted by Sun Pharmaceutical Industries Limited, an international, publicly listed pharmaceutical company with global operations (Customer) to be the local Australian sponsor, and to provide clinical research organisation (CRO) services, trial site services, and imaging analysis services (collectively, Services), for their clinical trial in Australia of a new drug compound (Clinical Trial).

Keep reading...Show less
  Island Pharmaceuticals

ISLA-101 Phase 2a/b PROTECT Clinical Trial Progress Update

Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; Island or the Company) is pleased to announce progress on its ISLA-101 Phase 2a/b clinical trial in dengue fever.

Keep reading...Show less
Amplia Therapeutics

Interim Data from Accent Pancreatic Cancer Trial Supports Continuation of Trial

Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to report the interim data analysis from the Company’s Phase 2a clinical trial investigating narmafotinib in the treatment of advanced pancreatic cancer (the ACCENT trial). The trial is investigating the combination of the Company’s best-in-class FAK inhibitor narmafotinib with the standard-of-care chemotherapy regimen of gemcitabine and Abraxane®. Data cut-off for the interim analysis is 27 September 2024.

Keep reading...Show less

Latest Press Releases

Related News

×